NEIMETH • NSE

Neimeth International Pharmaceuticals Plc

1.80

NGN

Open Price

1.80

Previous Close

1.80

Today’s Range

1.80 - 1.80

Number of Deals

Volume Traded

128,770.00

Value Traded

220,670.00

52 Weeks High

2.38

52 Weeks Low

1.26

Market Cap

3,418,482,794.40

YTD Price Performance

42.86 %

Audited Financial Statements for the Period Ended December 31st, 2023 - Neimeth International Pharmaceuticals Plc

Thursday, 4th at 2:55 PM

Neimeth International Pharm. Plc Appoints Valentine Chinedu Okelu as MD/CEO as Gerald I. Oputa Resigns

August 18th, 2023 at 9:17 AM

Neimeth International Pharmaceuticals Plc to Hold Board Meeting on July 27th 2023

July 13th, 2023 at 7:26 AM

Mrs Temitayo Nelson Resigns from the Board of Neimeth International Pharmaceuticals Plc

June 14th, 2023 at 4:25 PM

Neimeth International Pharmaceuticals Plc Concludes Rights Issue

February 10th, 2023 at 2:27 PM

Neimeth International Pharmaceuticals Plc Approves Q4 Financial Statement at Board Meeting

February 6th, 2023 at 3:26 PM

Neimeth International Pharmaceuticals Plc Reports N109.66m Loss in Q3'22 Unaudited Results, (SP:N1.38k)

November 23rd, 2022 at 10:31 AM

Neimeth International Pharmaceuticals Plc to Hold Board Meeting on October 27, 2022; Declares Closed Period

October 25th, 2022 at 4:34 PM

Neimeth International Pharmaceuticals Plc Approves Q2 2022 Financial Statement

August 18th, 2022 at 10:58 PM

Neimeth Holds Completion Board Meeting on N3.67bn Rights Issue

July 8th, 2022 at 12:26 PM

Key Stats

Shares Outstanding

1,899,157,108.00

Net Assets

1,469.34

Book Value Per Share

0.77

Sector P/E

57.84

EPS

-1.51

P/E

-1.19

ROE

0.00

Dividend Yield

3.89

About Company

Manufacturing & Marketing of Pharmaceuticals, Animal Health Products and general healthcare products.

Sector

Healthcare

Sub Sector

Pharmaceutical

Management

Pharm. Matthew O. Azoji

Mr Isaac Igbanoi

Mrs Florence Onyenekwe

Mrs. Temitayo O. Nelson

Mr Adekunle Adebowale

Barr. Ijezie. M. Emedosi

Address

Plot 16, Akanni Doherty Layout, Oregun Industrial Estate, Oregun, Lagos.

Phone No

+2349032543202 +2348159491935

Email Address

[email protected]

Website

https://www.neimethplc.com.ng/

Board of Directors

Non-Executive Director - Professor Maurice M. Iwu

Dr. A. B. C Orjiako

Mrs. Bashirat O. Odunewu

Non-Executive Director - Engr. Godwin E. Omene

Pharm. Matthew O. Azoji

Non-Executive Director - Phar. Sir. Ike Onyechi

Non-Executive Director - Prof. Elijah N. Sokomba

Mrs. Temitayo O. Nelson

Non-Executive Director - Thomas Tunbosun Osubu

Mazi Sam I. Ohuabunwa, (OFR)

Social Media Accounts

Subsidiary

Company Secretary

End of Accounting Year

30 Sep

Listing Date

21/09/1979

Company Registrar

Meristem Registrars and Probate Services Ltd,

Regulatory Status

CG+

Free Float

0.00

Auditor

PKF Professional Services, PKF Professional Services

Shareholding Pattern

Analyst Reports

Q1 2022 Unaudited Financial Statements for the Period Ended 31st December 2021 – Neimeth International Pharmaceutical Plc

March 17th, 2022 at 12:00 AM

Income

Profit & loss information

Description	Q 4, 2023 N'm	% Change
Gross Earnings	0.00	+ 0.00%
Profit Before Tax	-2,757.46	+ 0.00%
Income Tax Expense	-107.88	+ 0.00%
Taxation	-107.88	+ 0.00%
Profit After Tax	-2,865.34	+ 0.00%
Fixed Assets	3,664.78	+ 0.00%
Total Assets	8,935.10	+ 0.00%
Customers Deposits	0.00	+ 0.00%
Loans and Advances	0.00	+ 0.00%
Total Liabilities	7,465.76	+ 0.00%
Borrowings	0.00	+ 0.00%
Cash Flow From Operating Activities	0.00	+ 0.00%

Income

Description	Q 4, 2023 N'm	Q 2, 2022 N'm	Q 1, 2022 N'm	Q 4, 2021 N'm	Q 3, 2021 N'm
Gross Earnings	0.00	0.00	0.00	0.00	0.00
Gross Premium Written	0.00	0.00	0.00	0.00	0.00
Revenue	2,209.59	0.00	0.00	0.00	0.00
Turnover	0.00	1,827.00	192.00	2,839.00	1,991.00
Interest And Similar Income	0.00	0.00	0.00	0.00	0.00
Gross Premium Income	0.00	0.00	0.00	0.00	0.00
Cost Of Sales	-1,475.52	-1,103.00	-178.00	-1,330.00	-1,064.00

Description	Q 4, 2023 N'm	Q 2, 2022 N'm	Q 1, 2022 N'm	Q 4, 2021 N'm	Q 3, 2021 N'm
Property Plant And Equipment	3,664.78	1,932.00	1,453.00	1,412.00	1,354.00
Fair Value Movements On Equity Instruments	0.00	0.00	0.00	0.00	0.00
Value Through Profit Or Loss	0.00	0.00	0.00	0.00	0.00
Intangible Assets	0.00	0.00	0.00	0.00	0.00
Fair Value Movements On Debt Securities	0.00	0.00	0.00	0.00	0.00
Management Expenses	0.00	0.00	0.00	0.00	0.00
Other Non Current Assets	0.00	0.00	0.00	0.00	0.00

Description	Q 4, 2023 N'm	Q 2, 2022 N'm	Q 1, 2022 N'm	Q 4, 2021 N'm	Q 3, 2021 N'm
Cash Flow From Operating Activities	0.00	0.00	0.00	0.00	0.00
Total Premium Received	0.00	0.00	0.00	0.00	0.00
Receipt From Reinsurance Recovery	0.00	0.00	0.00	0.00	0.00
Reinsurance Premium Paid	0.00	0.00	0.00	0.00	0.00
Profit For The Period	-2,865.34	-134.00	-309.00	270.00	85.00
Commission Received	0.00	0.00	0.00	0.00	0.00
Claims Recoveries	0.00	0.00	0.00	0.00	0.00

Remark	Date
Notice of Board Director's meeting to consider and approve the Company’s Audited Financial Statements for the year ended 31st December 2023..	3/25/2024
Notice of board meeting to consider and approve the company's unaudited financial statements for quarter 3 ended 30th September 2023	10/26/2023
To consider and approve the Company’s Audited Financial Statements for the year ended December 31, 2022	3/29/2023
Q1 financial result for the period ended 31st December 2020 will be considered.	1/28/2021

Dividend	Dividend Type	Announement Date	Payment Date	Date
0.07	Final	12/29/2021		12/29/2021
6.50	Final	1/5/2021	3/12/2021	2/23/2021
0.05	Final	8/24/2011	10/10/2011	9/21/2011
0.12				8/29/2008
0.15				8/26/2007
0.10				10/16/2006
0.20				7/20/2005
0.15				8/13/2004
0.10				9/3/2002

Bonus	Bonus Type	Announement Date	Payment Date	Date
1F10	1F10	12/19/2018	1/18/2019	1/18/2019
1F10	1F10	12/22/2016		1/31/2017
1 for 5	1 for 5	1/31/2014		2/12/2014
1 for 4	1 for 4			8/29/2008
1 for 5	1 for 5			9/3/2002

New Face Value	Old Face Value	Exsplit Date	Announement Date

Book Closure	Address	Announement Date	Date
3/15/2022	NECA House, Plot A2, Hakeem Balogun Street, Alausa, Ikeja, Lagos	12/29/2021	3/22/2022
2/23/2021	NECA House Plot A2, Hakeem Balogun threet, Alausa, Ikeja, Lagos	1/5/2021	3/9/2021
	NECA House Plot A2, Hakeem Balogun threet, Alausa, Ikeja, Lagos	2/4/2020	3/5/2020
1/18/2019	Oranmiyan Hall, Lagos Airport Hotel Limited, Ikeja	12/17/2018	2/6/2019
1/31/2017	Lagos Airport Hotel, Ikeja, Lagos	12/22/2016	2/7/2017
3/18/2015	Airport Hotel,Ikeja,Lagos thate.	12/23/2014	3/24/2015
2/12/2014	Airport Hotel, Ikeja, Lagos	1/31/2014	3/17/2014
	Not yet available	4/8/2013	3/27/2013
9/21/2011	NULL	8/24/2011	9/30/2011
			10/21/2009

Technical Rating

Very Bullish
See details
View historical rating

Moving averages

Billish
Moving averages

Billish
Moving averages crossovers

Natural

Pivot levels

Trend	R1	R2	R3	PP	S1	S2	S3
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72

Note: This is just a sample text, change appropriately.

Moving average

Days
- HTML
- CSS
- JavaScript
5

1,344.77
10

1,344.77
20

1,344.77
50

1,344.77
100

1,344.77
200

1,344.77

Name of chart*

Technical Rating

Very Bullish
See details
View historical rating

Moving averages

Billish
Moving averages

Billish
Moving averages crossovers

Natural

Pivot levels

Trend	R1	R2	R3	PP	S1	S2	S3
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72

Note: This is just a sample text, change appropriately.

Moving average

Days
- HTML
- CSS
- JavaScript
5

1,344.77
10

1,344.77
20

1,344.77
50

1,344.77
100

1,344.77
200

1,344.77

Name of chart*

Technical Rating

Very Bullish
See details
View historical rating

Moving averages

Billish
Moving averages

Billish
Moving averages crossovers

Natural

Pivot levels

Trend	R1	R2	R3	PP	S1	S2	S3
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72

Note: This is just a sample text, change appropriately.

Moving average

Days
- HTML
- CSS
- JavaScript
5

1,344.77
10

1,344.77
20

1,344.77
50

1,344.77
100

1,344.77
200

1,344.77

Q 4, 2023

Price to book

2.33
Price to sales

1.55
Dividend yield

3.89
Net Debt

-2,252.83
Price Earning Including Extra Items

-1.19
Price Earning Normalized

-1.24
Price To Free Cash Flow

-4.42
Price To Tangible Book

0.38

Margin Ratio
Q4

Q 4, 2023

Gross Revenue Margin

166.78
Gross Profit Margin

166.78
Net Interest Margin

0.00
Net Profit Margin

-129.68
Operating Cash Flow/Revenue

-35.00
Operating Profit Margin (%)

0.00
Pretax Margin

-124.80

Growth Ratio
Q4

Q 4, 2023

Book Value Growth Rate

35.17
Capital Expenditure Growth Rate

0.00
Deposit Growth

0.00
Dividend Growth

-98.92
EBITDA

0.00
EPS Growth Rate

2,038.31
Fixed Asset Growth

89.69
Impairment Growth

0.00
Loan Growth

0.00
Net Assets growth

35.17
Net Profit Margin Growth Rate

-100.00
Operating Cash Flow

-773.41
Revenue Growth

20.94
Shareholder Fund Growth

35.17
Total Assets Growth

32.25
Total Liabilities Growth

31.69

Per Share Ratio
Q4

Q 4, 2023

Book Value per share

0.77
Cash Per Share

1.19
Dividend Per Share

0.07
EPS Basic Excl. Extra Items

-1.51
EPS Excl. Extra Items

-1.51
EPS Incl. Extra Items

0.00
EPS Normalized

-1.51
Revenue Per Share

1.16

Financial Strength Ratio
Q4

Q 4, 2023

Acid Test Ratio

0.46
Claims Ratio

0.00
Cost to Income Ratio

0.00
Current Ratio

0.75
Investment Ratio

0.00
Leverage Ratio

0.00
Liquidity Ratio

0.25
Long Term Debt/Equity

0.00
Net Interest Coverage

0.00
Payout Ratio

-0.05
Quick Ratio

0.46
Reserve Ratio

0.00
Total Debt/Total Equity

0.00

Management Effectiveness Ratio
Q4

Q 4, 2023

Annual % Change in Highest Directors Pay

0.00
Annual % Change in PBT

1,957.81
Annual % Change in Share Price

-7.22
Annual % Change in Staff Cost

0.00
Asset Turnover

0.25
Dividend Payout Ratio

-0.05
Highest Directors’ Pay to PBT Ratio

0.00
Highest Directors’ Pay to Revenue Ratio

0.00
Highest Directors’ Pay vs PBT

0.00
Highest Directors’ Pay vs Revenue

0.00
Highest Directors’ Pay vs Staff Cost

0.00
Inventory Turnover

-0.71
Net Income/Employee

0.00
Receivables Turnover

0.00
Return on Assets

-0.31
Return on Average Assets

-0.37
Return on Average Equity

0.00
Return on Equity

0.00
Return on Investment

0.00
Revenue/Employee

0.00
Staff Cost vs PBT

0.00
Staff Cost vs Revenue

0.00

Price performance

1 week

-1.10%

1 month

2.86%

3 months

-10.89%

6 months

16.13%

9 months

-2.70%

1 years

42.86%

Volume analysis

1 week

72.82%

1 month

-73.23%

3 months

-96.46%

6 months

50.33%

9 months

-75.56%

1 years

173.98%

RELATED MEDIA

SIMILAR STOCKS

FIDSON Pharmaceutical

15.90 NGN 0%

MAYBAKER Pharmaceutical

6.00 NGN 0%

MECURE Pharmaceutical

9.72 NGN 0%

Proshare is a professional practice focused on delivering research and information services to bridge the gap between investors and markets; by delivery on credible, reliable, and timely engagements through the following areas — Impact Research, Market Intelligence, Strategic Advisory, Stakeholder Relations & Digital Media.